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Ophthalmology Volume 120, Number 9, September 2013pathophysiology in LHON. In this study, we reported that ganglion
cell analysis could precisely detect the loss of retinal ganglion cell in
a time-dependent manner during early phase of LHON when RNFL
thickness had not decreased yet. We also raise the possibility that
there might be many more patients>60 years of age with visual loss
owing to LHON than we have supposed previously. It may be worth
investigating mtDNA point mutations regardless of age if a patient
presents with unknown visual acuity loss with central scotoma.
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Ranibizumab in Myopic Choroidal
Neovascularization: The 12-Month
Results from the REPAIR Study
The REPAIR study was a phase II, prospective, multicenter,
industry-sponsored study (clinical trial registration: http://clinical-
trials.gov/; identiﬁer: NCT01037348) of intravitreal ranibizumab in
myopic choroidal neovascularization (CNV). The purpose was to
collect data in a validated robust manner to describe the visual,
anatomic, and patient-reported outcome measures in a large cohort
of treatment-naïve patients with myopic CNV after intravitreal
ranibizumab as primary and ﬁrst-line therapy using a pragmatic
retreatment algorithm. Detailed methodology has previously been
reported.1 Brieﬂy, patients were eligible if they had subfoveal or
juxtafoveal CNV secondary to pathologic myopia and best-
corrected visual acuity (BCVA) of between 20 of 32 and 20 of
320 (78e24 Early Treatment of Diabetic Retinopathy Study letters)
in the study eye. Pathologic myopia was deﬁned as myopic
spherical equivalent of 6 diopters (preoperatively if the eye had
previously undergone cataract or refractive surgery) and active
CNV was diagnosed using spectral domain optical coherence1944tomography (OCT) and fundus ﬂuorescein angiography. In the
planned interim analysis at 6 months, the mean gain in BCVA was
12.2 letters.1 This report summarizes the primary, secondary, and
exploratory outcomes at 12 months. Demographic and baseline
characteristics of 65 enrolled patients across 12 sites are shown in
Table 1 (available at http://aaojournal.org). Median number of
injections over 12 months was 3 (mean, 3.6). After the ﬁrst
baseline injection, retreatment rates for proportions of patients
over 12 months were 0 (21.5%), 1 (18.5%), 2 (16.9%), and 3
(15.4%). The median time to ﬁrst retreatment (time to retreatment
for 50% of patients) was 2 months (95% conﬁdence interval,
1.25e3.42).
The primary outcome in terms of mean change in BCVA score
on the Early Treatment of Diabetic Retinopathy Study eye chart
was 13.8 letters (standard deviation [SD], 14.0; 95% conﬁdence
interval, 10.2e17.3; P<0.001) at 12 months from a baseline level
of 59.5 letters (20/63; SD 13.6; Fig 1; available at http://
aaojournal.org). The greatest improvement was observed in the
ﬁrst month of treatment (mean change, þ8.7 letters). Overall,
86% of patients showed improvement in mean BCVA score, with
24 patients (36.9%) achieving a BCVA gain of 15 letters in the
study eye, and 50.8% of patients achieving a gain of 10 letters.
Only 1 patient (1.5%) experienced a loss of 15 letters in the
study eye. This patient developed a macular hole at visit 8 and
despite the visual loss demonstrated a reduction in OCT
measurements of 150 mm over the course of the study. At
baseline, 73.8% of study eyes were the worse-seeing eyes; by
month 12 this percentage had reduced to 59.4%. The status of study
eyes improved from worse-seeing eye to better-seeing eye in 14.4%
of patients.
There was also a signiﬁcant mean reduction in central macular
thickness (CMT; 500 mm radius around the fovea) by 135 mm from
baseline to month 12 (SD, 134 mm; P<0.001). Mirroring visual
acuity improvement, the greatest improvement in mean CMT was
observed within the ﬁrst month (109 mm; SD, 127 mm). A
correction for differences between OCT machines used in the study
(Heidelberg [Spectralis], Zeiss [Cirrus], or Topcon) was not
required because the anatomic endpoint was a mean change in
CMT. The mean change in lesion size on ﬂuorescein angiogram
was 0.37 mm2 (SD, 1.2; P ¼ 0.0287).
Individual investigators graded OCT scans qualitatively for the
presence of subretinal ﬂuid as well as intraretinal cysts, ﬂuid, or
edema. The proportion of eyes with subretinal ﬂuid decreased from
67.7% to 7.7% (P<0.001, McNemar test); proportion with intra-
retinal cysts, 52.3% to 13.8%; proportion with edema, 87.7% to
7.7%.
For the 2 exploratory patient-reported outcomes, 61 patients
completed the 12-item Wellbeing Questionnaire and the Macular
Treatment Satisfaction Questionnaire. The general well-being score
(out of 36) was signiﬁcantly improved at month 12 compared with
baseline (27.3 vs 25.6; P ¼ 0.03), and a signiﬁcant improvement in
the overall Macular Treatment Satisfaction Questionnaire score (out
of 72) was also observed (64.9 vs 55.0; P ¼ 0.0001).
There was 1 case of culture-negative endophthalmitis; 3
nonfatal, nonocular serious adverse events, which were unrelated to
study treatment; and no retinal detachments (Table 2; available at
http://aaojournal.org).
The REPAIR study is the largest multicenter, prospective study
to date of the treatment of myopic CNV with ranibizumab. The
primary outcome in terms of mean change in BCVA at 12 months
Reportswas 13.8 letters. This is comparable with recent but smaller studies
of ranibizumab therapy in myopic CNV.2e4 Encouraging
improvements in patient-reported outcome measures were also
found and retreatment rates were low.
One limitation of the study was the lack of a reading center.
Observer variation may explain the high frequency of subretinal
ﬂuid graded by individual investigators at baseline. Alternatively,
the high rate may represent misclassiﬁcation, because it has
previously been shown that human graders are good at agreeing
whether ﬂuid is present or absent, but are poor at distinguishing
subretinal from intraretinal ﬂuid.5 Because any ﬂuid present on
OCT would drive retreatment, misclassiﬁcation would not affect
the decision to treat.5 However, possible grading inconsistencies
should not affect our main conclusion regarding the primary
visual outcome and the quantitative anatomic outcomes. The
other limitation was the lack of a control arm. Both of these
limitations should be better addressed in future comparative trials
such as the phase III RADIANCE study comparing ranibizumab
with verteporﬁn-PDT (clinicaltrials.gov identiﬁer NCT01217944).
Currently, this report provides a useful evidence to support the use
of primary ranibizumab therapy in treatment-naïve myopic CNV,
gives an estimate of the likely burden of treatment, and provides
a pragmatic retreatment algorithm, that is easily translated into
clinical practice.
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Two Year SAVE Outcomes: 2.0 mg
Ranibizumab for Recalcitrant
Neovascular AMD
The Super-dose Anti-VEGF (SAVE) trial assessed the efﬁcacy of
2.0 mg ranibizumab (0.05 ml), a 4-fold higher dose than the 0.5 mg
dose approved by the US Food and Drug Administration, for the
management of recalcitrant neovascular age-related macular
degeneration (AMD) in 88 patients.1,2 Primary outcome results of
the 3-month, ﬁxed-interval dosing period were reported in
Ophthalmology, and in this report we offer 2-year follow-up data.
Recalcitrant ﬂuid despite monthly or near-monthly anti-vascular
endothelial growth factor (VEGF) therapy is a common clinical
scenario in the management of neovascular AMD. Indeed, more
than one half of patients treated with anti-VEGF agents in
prospective neovascular AMD trials manifest residual intraretinal,
subretinal, or subretinal pigment epithelium ﬂuid despite maximal
anti-VEGF dosing.3 This persistent macular edema likely limits
maximal visual recovery in these challenging cases.4
Higher dose of existing anti-VEGF agents, as assessed
prospectively in SAVE, is a potential route for managing these
incomplete responders. At study entry, patients had received an
average of 24 previous intravitreal injections of anti-VEGF agents,
including monthly dosing in the year before enrollment (mean time
between injections of 31 days). After 3 monthly 2.0 mg doses,
patients were evaluated every 4 weeks (cohort A) or every 6 weeks
(cohort B) and retreated as needed (PRN) for any intraretinal,
subretinal, or subretinal pigment epithelium ﬂuid detected on
spectral domain optical coherence tomography (SD OCT).
After 3 monthly treatments, mean Early Treatment Diabetic
Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA)
improvedþ3.3 letters (P ¼ 0.001) and mean SD OCT central retinal
subﬁeld thickness (CST) improved e33.1 mm (P ¼ 0.01).1 Visual
gains were maintained through month 12,2 with cohorts A and B
gaining a mean of þ4.1 and þ3.7 ETDRS letters, respectively, after
receiving a mean of 11.6 (cohort A) and 8.6 (cohort B) injections.2
Anatomically, monthly PRN retreatment led to continued retinal
detergescence through year 1, whereas every 6 week PRN1945
Table 1. Baseline Demographics, Study Eye Characteristics, and
Lesion Characteristics in the REPAIR Trial (safety set; n ¼ 65)
Baseline Demographics
Mean age (y) 55.5
Age, n (%) patients
<50 21 (32.3)
50e65 29 (44.6)
65e75 10 (15.4)
>75 5 (7.7)
Female, n (%) 46 (70.8)
Caucasian, n (%) 59 (90.8)
Mean weight (kg) 76.8
Mean PM duration (y) 39.89
Median PM duration (y) 43.85
Mean CNV duration (mos) 1.78
Median CNV duration (mos) 0.56
Baseline Study Eye Characteristics
Mean visual acuity, letters (SD) 59.5 (13.59)
Median visual acuity, letters 60.0
Visual acuity, n (%)
23e37 letters 4 (6.2)
38e52 letters 16 (24.6)
53e67 letters 25 (38.5)
68e82 letters 19 (29.2)
>82 letters 1 (1.5)
Mean CMT, mm (SD) 384.7 (130.8)
Median CMT, mm 390
Study eye worse than fellow eye at start % patients 73.8
Study eye better than fellow eye at start % patients 26.2
Baseline Lesion Characteristics
Subretinal/intraretinal hemorrhage, n (%) 41 (63.1)
CNV location in relation to the fovea, n (%)
Subfoveal 43 (66.2)
Juxtafoveal 17 (26.2)
Probably subfoveal/juxtafoveal 5 (7.7)
Mean area of lesion (mm2) 1.46
Median area of lesion (mm2) 1.01
CMT ¼ central macula thickness; CNV ¼ choroidal neovascularization;
PM ¼ pathologic myopia; SD ¼ standard deviation.
Table 2. Adverse Events Observed up to 12 Months in the
REPAIR Trial (safety set; n ¼ 65)
Adverse Event No. of Patients (%)
Ocular
Anterior chamber inﬂammation 1 (1.5)
Blepharitis 1 (1.5)
Blindness 1 (1.5)
Choroidal neovascularisation 1 (1.5)
Conjunctival hemorrhage 4 (6.2)
Conjunctival hyperemia 1 (1.5)
Corneal abrasion 1 (1.5)
Endophthalmitis 1 (1.5)
Eye discharge 1 (1.5)
Eye inﬂammation 1 (1.5)
Eye pain 7 (10.8)
Eyelid pain 1 (1.5)
Foreign body sensation in eye 3 (4.6)
Glaucoma 1 (1.5)
Hordeolum 1 (1.5)
Hyphema 1 (1.5)
Intraocular pressure increase 2 (3.1)
Metamorphopsia 2 (3.1)
Normal tension glaucoma 1 (1.5)
Ocular discomfort 1 (1.5)
Photophobia 1 (1.5)
Procedural pain 1 (1.5)
Punctate keratitis 1 (1.5)
Retinal detachment 1 (1.5)
Retinal tear 1 (1.5)
Tenderness 1 (1.5)
Trabulectomy 1 (1.5)
Ulcerative keratitis 1 (1.5)
Vision blurred 2 (3.1)
Visual acuity reduced 2 (3.1)
Visual impairment 1 (1.5)
Vitreous detachment 1 (1.5)
Vitreous ﬂoaters 4 (6.2)
Nonocular (5%)
Lower respiratory tract infection 5 (7.7)
Nasopharyngitis 6 (9.2)
Fall 4 (6.2)
Back pain 4 (6.2)
Headache 4 (6.2)
Cough 4 (6.2)
Serious
Endophthalmitis 1 (1.5)
Joint dislocation 1 (1.5)
Depression 1 (1.5)
Figure 1. Visual acuity of study and fellow eye.
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